Q1 2020 13F Holders as of 31 Mar 2020
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
126,468,243
-
Total 13F shares
-
67,992,711
-
Share change
-
+11,296,204
-
Total reported value
-
$1,305,743,291
-
Put/Call ratio
-
133%
-
Price per share
-
$19.21
-
Number of holders
-
135
-
Value change
-
+$217,084,502
-
Number of buys
-
80
-
Number of sells
-
72
Institutional Holders of Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) as of Q1 2020
As of 31 Mar 2020,
Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) was held by
135 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
67,992,711 shares.
The largest 10 holders included
Consonance Capital Management LP, Avoro Capital Advisors LLC, BlackRock Inc., Palo Alto Investors LP, ADAGE CAPITAL PARTNERS GP, L.L.C., JANUS HENDERSON GROUP PLC, VANGUARD GROUP INC, STATE STREET CORP, D. E. Shaw & Co., Inc., and ALKEON CAPITAL MANAGEMENT LLC.
This page lists
135
institutional shareholders reporting positions in this security
for the Q1 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.